Floatz logo

CD16/IL15/CD33 TRISPECIFIC KILLER CELL ENGAGER

Mast Cell Leukemia

GT Biopharma, Inc.protein_peptidePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Mast Cell Leukemia cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
Stanford University
Phase 2BB
Fludarabine
Fred Hutchinson Cancer Center
Phase 2BB
Avapritinib
Blueprint Medicines Corporation
Phase 2BB
Solu-Cortef
Stanford University
Phase 2B
Brentuximab Vedotin
Jason Robert Gotlib
Phase 2B

View all 24 →

Same molecule, other indications

CD16/IL15/CD33 TRISPECIFIC KILLER CELL ENGAGER is also rated in:

myelodysplastic syndromeDormant
CCC
Indicative ·
48 / 100
View asset →
systemic mastocytosisDormant
CCC
Indicative ·
48 / 100
View asset →
acute myeloid leukemiaDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →